Citius Pharmaceuticals' (CTXR) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.
Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.
The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.
Price: 4.22, Change: +0.31, Percent Change: +7.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments